Insular XXXX associated with different transition probabilities to @entity716 .

@entity1032 @entity1833 @entity10260 @entity854 @entity716
BACKGROUND: Although individuals vulnerable to @entity716 show brain @entity854 , structural alterations underlying different probabilities for later transition are unknown. The present study addresses this issue by means of voxel-based morphometry (VBM). METHOD: We investigated grey matter volume (GMV) abnormalities by comparing four neuroleptic-free groups: individuals with first episode of @entity716 (FEP) and with @entity1032 ( @entity10260 ), with either long-term ( @entity10260 -LT) or short-term @entity10260 ( @entity10260 ), compared to the healthy control (HC) group. Using three-dimensional (3D) magnetic resonance imaging (MRI), we examined 16 FEP, 31 @entity10260 , clinically followed up for on average 3 months ( @entity10260 , n=18) and 4.5 years ( @entity10260 -LT, n=13), and 19 HC. RESULTS: The @entity10260 group showed less GMV in the right and left insula compared to the @entity10260 -LT (Cohen's d 1.67) and FEP groups (Cohen's d 1.81) respectively. These GMV differences were correlated positively with global functioning in the whole @entity10260 group. Insular alterations were associated with negative symptomatology in the whole @entity10260 group, and also with @entity1833 in the @entity10260 and @entity10260 -LT subgroups. We found a significant effect of previous antipsychotic medication use on GMV abnormalities in the FEP group. CONCLUSIONS: GMV abnormalities in subjects at high clinical risk for @entity716 are associated with negative and positive @entity716 , and global functioning. Alterations in the right insula are associated with a higher risk for transition to @entity716 , and thus may be related to different transition probabilities.
